Aerosolized Interferon-α1b Anti-RSV Efficacy and Safety in Preclinical Models

A 12.0 KB document authored by Mingming Yang and last updated in April 2026 details a preclinical study on aerosolized human interferon-α1b (IFN-α1b). The study reports an in vitro EC₅₀ of 4.64 ng/mL against respiratory syncytial virus (RSV) and a 3.33% absolute systemic bioavailability in cynomolgus monkeys. It concludes that aerosolized IFN-α1b demonstrated greater viral load reduction than ribavirin in mice and was well-tolerated in monkeys.

Use Cases

• Benchmarking antiviral drug efficacy based on reported in vitro EC₅₀ values and in vivo viral titer reductions.
• Studying lung-targeted pharmacokinetics based on the reported respiratory drug exposure and systemic bioavailability in monkeys.
• Assessing preclinical safety profiles based on the described repeat-dose inhalation toxicity and reversible lung inflammation findings.

Strengths

• Contains specific quantitative results, including an in vitro EC₅₀ of 4.64 ng/mL and a systemic bioavailability of 3.33%.
• Provides comparative efficacy data, showing greater viral load reduction than ribavirin in the tested mouse model (p < 0.001).
• Includes safety assessment from a repeat-dose study in cynomolgus monkeys at 18 μg/kg/day.

Limitations

• The dataset is a 12.0 KB DOCX file, indicating a very limited scope, likely a summary table or manuscript rather than raw experimental data.
• Row count and column-level documentation are absent; data structure and semantics must be inferred from the document text.
• Description metadata is limited; actual data quality and completeness require manual inspection after download.

Provenance

Source

figshare, author Mingming Yang.

Collection Method

Likely contains summarized results from in vitro assays, mouse model experiments, and monkey pharmacokinetic/toxicology studies.

Freshness

Last updated 2026-04-30 05:40:08; freshness should be verified.